At Notable Labs, we focus on personalized drug discovery for blood cancer by testing combinations of approved drugs on patients' actual cells.

At Isomorphic Labs, we collaborate with various companies to generate proprietary data, which has proven to be impactful in drug development.

Biotech companies often use their time in Y Combinator to conduct critical path experiments and work with external companies for proof of concept studies, which can advance their regulatory filing status.

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

Access to capital and FDA's development strategies for rare diseases have enabled small biotech companies to bring products to market without being acquired.

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

We've validated our business model by addressing a critical need in the developing world with a simple, easy-to-use, portable liver function test, which is appealing to major pharmaceutical companies.

Successful biotech funds often incubate ideas internally before spinning them out as independent companies, which has proven effective in the industry.

Science Exchange connects pharmaceutical companies with early-stage biotech firms, facilitating advancements in cancer biology and other areas. The application of artificial intelligence in the biological sector is leading to innovations in predicting drug efficacy and toxicity during the preclinical stage, which helps avoid clinical failures.